Why we work on Alzheimer’s disease

Housed within the Target Discovery Institute, the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) juxtaposes drug discovery expertise alongside scientific and academic understanding of patients, disease mechanisms and model systems. The burden caused by Alzheimer’s disease and other dementias represents one of the biggest problems for our healthcare systems. The last medicine was approved in 2002 and today we only have symptomatic treatments. ARUK-ODDI brings together chemists, biologist, psychiatrists and neuroscientists, many of them with pharmaceutical background, aiming to accelerate the discovery of novel and effective treatments.

You can listen to Why we work on Alzheimer’s disease online on Radio and Podcast. Open the player on this page to stream the available audio.

Why we work on Alzheimer’s disease is an episode from Translational Medicine by Oxford University.

This episode is 6:30 long.

This episode was published on Nov 30, 2016.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Translational Medicine when more episodes are available from the podcast feed.